Secondary outcomes Secondary outcomes included cardiovascular mortality, all-cause mortality, non-fatal myocardial infarction (MI) and stroke, as well as hospitalisation for heart failure
Scope: Comprehensive review of ANGPTL3 inhibition as a therapeutic strategy to reduce triglyceride-rich lipoproteins and residual cardiovascular risk Therapeutic approaches discussed: Monoclonal antibodies (e.g., evinacumab) RNA-based therapies (ASOs and siRNA: vupanorsen, zodasiran, solbinsiran) Emerging gene-editing strategies (CRISPR/base editing) Key message: Targeting ANGPTL3 provides robust reductions in triglycerides, apoB-containing lipoproteins, and non-HDL cholesterol, independently of the LDL receptor Clinical relevance: Positions ANGPTL3 inhibition as a next-generation approach for managing mixed dyslipidemia and lipid-related residual risk beyond LDL-C Laura Schreier Natalia Nardelli European Atherosclerosis Society To view or add a comment, sign in Tipping the Scale in MASH: The TZD vs
The sublingual route eliminates the need for a needle, which could lead to a better experience for many
Ozempic is FDA-approved for type 2 diabetes, so Anthem covers it for that indication regardless of employer benefit design
I was evaluated by Dr
How quickly will I notice hormonal improvements on semaglutide
